AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05975489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
Study NCT05975489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
Study NCT03137810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental cord drainage
Description: In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad.
Study NCT03137810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non placemtal cord drainage
Description: In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
Study NCT03627104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normoprotein diet with animal protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
Study NCT03627104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normoprotein diet with vegetable protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
Study NCT03627104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-protein diet with animal protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
Study NCT03627104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-protein diet with vegetable protein
Description: ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
Study NCT02930694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (capsule)
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
Study NCT02930694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (suspension)
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
Study NCT03043053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: oxytocin intranasal spray
Study NCT03043053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT03023995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF with Platelet rich fibrin
Description: In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
Study NCT03433508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal
Description: 2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
Study NCT03433508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive
Description: To maintain the target Hemoglobin of 7 to 8 gm/dL.
Study NCT04285138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phantom limb exercise
Description: phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
Study NCT04285138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror \[Figure 1\]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity
Study NCT03023995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF with connective tissue graft
Description: In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
Study NCT02008526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages Transmitted by Peer Health Educators (TXT-PHE)
Description: Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
Study NCT02008526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages Transmitted by Automation (TXT-Auto)
Description: Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
Study NCT02816723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: mindfulness/meditation/movement training
Study NCT02816723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health
Description: Brain Health Education
Study NCT01806181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study NCT02845674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Description: 0.09% cyclosporine nanomicellar solution
Study NCT02139397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Study NCT02139397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT03618875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ice pack
Description: ice pack was placed on eyelid 5 minutes prior to IVIT
Study NCT03618875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: room temperature pack
Description: room temperature pack was placed on eyelid 5 minutes prior to IVIT
Study NCT00176449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: 150mg twice a day (starting with 150mg once a day for three days)
Study NCT00176449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Comparable placebo
Study NCT03406520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated disk
Description: The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
Study NCT03699748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Worker Intervention
Description: Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
Study NCT03699748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by Unite Here Health and local oncologists
Study NCT03699748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by Unite Here Health and local oncologists
Study NCT04346316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)
Study NCT04346316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)
Study NCT04294277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
Study NCT00296517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 (Bupropion Hydrochloride Sustained Release)
Description: Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
Study NCT00296517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Study NCT01700491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Catheter 0.2% ropivacaine
Description: 0.2% ropivacaine into epidural space and saline into paravertebral space
Study NCT01700491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Catheter 0.4% ropivacaine
Description: 0.4% ropivacaine into paravertebral space and saline into the epidural space
Study NCT02814526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
Study NCT02814526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/balance/range of motion exercise
Description: The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
Study NCT01769547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
Study NCT01621009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bupropion + counseling
Description: Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date.
Study NCT04484103 — intervention group
Intervention type: OTHER
Intervention: Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.
Description: The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used.
Study NCT01621009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bupropion, No counseling
Description: Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks
Study NCT01621009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication + counseling
Description: Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.
Study NCT01621009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication, No counseling
Description: Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks
Study NCT02147301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead
Description: Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first.
Study NCT02771756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zhen qishen capsule and Oral Supplement of Yuyikang
Study NCT02771756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo
Study NCT02771756 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy
Study NCT02771756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT02771756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nutrition education
Study NCT02771756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Study NCT01357772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT01357772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01551667 — intervention group
Intervention type: BIOLOGICAL
Intervention: Antibody assays for S. aureus
Description: Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
Study NCT03041051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Study NCT03041051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23
Study NCT05014711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Study NCT01551667 — intervention group
Intervention type: BIOLOGICAL
Intervention: Basic blood work
Description: Hemogramme + CRP on Days 0, 2, 4 and 7
Study NCT00004233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00004233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00004233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triacetyluridine
Study NCT02774889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stepping Online
Description: Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources
Study NCT01213238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
Study NCT01213238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
Study NCT05014711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Study NCT01213238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on day 1 of a 21 day cycle.
Study NCT01178788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha-hydroxy progesterone caproate
Description: weekly injection of 17 P
Study NCT01178788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized Progesterone
Description: daily administration of vaginal progesterone
Study NCT01178788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT04260113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib orally 500mg once daily half an hour after meal
Study NCT04227834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health hygiene education
Description: A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
Study NCT04227834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health hygiene education
Description: A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
Study NCT04368169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Teramune Botanical Extract
Description: Combination blend of aromatic plant extracts in an emulsifier carrier.
Study NCT04368169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Emulsifier carrier without active supplement ingredients.
Study NCT02650375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metatinib Tromethamine
Description: Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.